Overview

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Phase:
Phase 2
Details
Lead Sponsor:
Aldeyra Therapeutics, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions